bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, announces the launch of ioAstrocytes.
bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain Read More »
The Lupus Research Alliance announced the recipients of the 2024 Lupus Insight Prize to Marko Radic, Ph.D., The University of Tennessee Health Science Center, and Georg Schett, M.D., Friedrich-Alexander-Universität Erlangen-Nürnberg, for their groundbreaking discoveries in utilizing CAR T cell therapy to potentially revolutionize lupus treatment.
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces that Raju Kucherlapati, PhD, has been appointed Chair of the Board of Directors, effective immediately, following his role as interim Chair since June 2023.
Biophytis SA announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 in Latin American including, but not limited to Brazil, Mexico, Argentina and Colombia.
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
Sensorion announces that promising new data and analysis results from the SENS-401 following cochlear implantation Phase 2a clinical study will be presented at the 17th International Conference on Cochlear Implants and Other Implantable Technologies taking place on July 10-13, 2024, in Vancouver, Canada.
GenSight Biologics announced the renegotiation of certain financial obligations, securing its financial position and improving short-term flexibility.
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates Read More »
Vanda Pharmaceuticals Inc. announced that the Company’s Board of Directors has determined that the unsolicited proposal from Cycle Group Holdings Ltd to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights both substantially
GC Cell, a fully integrated cell and gene therapy pioneer, is proud to announce the establishment of an MOU for strategic partnership with Bifarma, a frontrunner in stem cell therapy within Indonesia with comprehensive capabilities in R&D, GMP-compliant manufacturing, and the commercialization of cell therapies.
GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group Read More »
By effectively communicating with colleagues, you can improve collaboration as well as your own work experience. It all starts with active listening.
Better Collaboration: 7 Tips for Effective Workplace Communication Read More »
